ICON Public Limited (NASDAQ:ICLR) Shares Purchased by Entropy Technologies LP

Entropy Technologies LP grew its position in shares of ICON Public Limited (NASDAQ:ICLR) by 472.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,174 shares of the medical research company’s stock after purchasing an additional 5,095 shares during the period. Entropy Technologies LP’s holdings in ICON Public were worth $1,295,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Whittier Trust Co. grew its holdings in shares of ICON Public by 12.3% in the third quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after purchasing an additional 441 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of ICON Public by 23.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares in the last quarter. Arkadios Wealth Advisors increased its position in shares of ICON Public by 5.0% during the third quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after acquiring an additional 62 shares during the period. First Horizon Advisors Inc. raised its stake in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 151 shares in the last quarter. Finally, Icon Wealth Advisors LLC boosted its holdings in ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after purchasing an additional 11,840 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

ICON Public Stock Down 1.3 %

Shares of NASDAQ ICLR opened at $190.85 on Tuesday. The stock has a market cap of $15.75 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 1.78 and a beta of 1.19. ICON Public Limited has a 52-week low of $183.38 and a 52-week high of $347.72. The business has a 50-day moving average price of $207.07 and a 200 day moving average price of $252.73. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. cut their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. TD Cowen reduced their target price on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Robert W. Baird lowered their price target on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Leerink Partners restated an “outperform” rating and issued a $255.00 price objective (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Finally, Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $285.75.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.